Mark Levin to Host Original Podcast Series
On the Frontlines with Mark Levin and Yael Eckstein ~ Presented by The International Fellowship of Christians and Jews Four-Part […]
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already […]
LifeWallet Acquires Assignment of Additional MSP Claims with an Overall Paid Amount Exceeding $10.6 billion Comprised of Over 450,000 Medicare Members and Announces it Secured a Waiver of Acceleration on a Second Loan Agreement in the Event of a Negative Going Concern
MIAMI, Oct. 02, 2024 (GLOBE NEWSWIRE) — MSP Recovery, Inc. d/b/a LifeWallet (NASDAQ: LIFW) (“LifeWallet” or “the Company”), as previously announced on August […]
PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA
TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology […]
American Rebel Holdings, Inc. Ships Re-Stocking Order from Kansas’ Standard Beverage for American Rebel Light Beer
Nashville, TN, Oct. 02, 2024 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. (NASDAQ: AREB) (“American Rebel” or the “Company”), the […]
Navient to announce third quarter 2024 results, host earnings webcast Oct. 30
HERNDON, Va., Oct. 02, 2024 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI) will host an audio webcast to review its 2024 […]
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy […]
Yes, Chef! AGS is Cookin’ Up A Feast of Epic Proportions at G2E 2024
LAS VEGAS, Oct. 02, 2024 (GLOBE NEWSWIRE) — Global gaming supplier AGS (NYSE: AGS or “the Company”) will serve a […]
Mullen Announces Significant Revenue Increase and Reduction in Spending
For quarter ended Sept. 30, 2024, Company expects to report approximately $4.5 million in revenue compared to $65,235.00 reported in […]
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
MIAMI, Oct. 02, 2024 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular […]
